Medical disclaimer: Peptide Clinic Finder is an informational directory and does not diagnose, prescribe, or recommend treatments. Always consult a qualified clinician for medical decisions.

Semaglutide vs Sermorelin

Semaglutide is associated with weight management pathways while sermorelin appears in hormone optimisation and longevity contexts. Use clinic profiles to compare service scope and clinician oversight.

Semaglutide and sermorelin typically appear in different clinical contexts — metabolic health versus hormone optimisation. If a clinic offers both, ask how each fits into its assessment model and monitoring plan. This page is for comparing provider approaches, not clinical suitability.

Semaglutide

A GLP-1 receptor agonist used in weight management and metabolic health programmes.

Potential benefits

  • Widely referenced in weight-management clinics.
  • Often paired with lifestyle and monitoring support.

Considerations

  • Requires licensed prescriber oversight.
  • Suitability depends on individual assessment.
Best for: Comparing weight-management providers and their clinical governance.

Sermorelin

A growth hormone–releasing hormone analogue listed in longevity and hormone optimisation clinics.

Potential benefits

  • Commonly referenced in longevity protocols.
  • Often paired with other secretagogues.

Considerations

  • Evidence quality varies by clinic and jurisdiction.
  • Requires structured monitoring.
Best for: Comparing hormone optimisation clinics and consultation depth.
CategorySemaglutideSermorelin
Directory contextRecovery / performance-focused listing context.Weight / metabolic or longevity listing context.
Common goalsRecovery support, injury pathways, performance.Weight management, metabolic health, longevity programs.
Guidance noteInformational listing only; suitability requires clinician review.Informational listing only; suitability requires clinician review.

Related clinics

Conclusion

These are often offered by different types of clinics. Choose based on your goal and the provider’s clinical governance rather than the peptide label.

Related peptide pages